Oncology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      Aim for deep response (uMRD) as part of your patients' treatment goals

      Science of deep response

      Achieving deep response early can help improve survival outcomes for patients with CLL1-3

      Deep response, or undetectable minimal residual disease (uMRD), is defined as <1 tumour cell per 104 white cells. It is a powerful prognostic tool that demonstrates an inverse relationship with patient outcomes.1

      How low can you go?

      Select a patient to see how choosing a treatment capable of achieving deep response could improve their outcomes1

      Hypothetical scenarios of CLL burden during and after therapy.
      Adapted from Bottcher et al, 2013.1
      CLL = chronic lymphocytic leukaemia; MRD = minimal residual disease.

       

      Survival benefits

      Early deep responses have been associated with long-term PFS and OS2,3

      In a retrospective analysis of 133 patients with CLL (1996–2007), deep response was found to be a predictor of PFS and OS in first-line and R/R settings.2

      10-year PFS according to MRD status2

      Adapted from Kwok M, et al. 2016

      Of the 133 patients analysed: 57 were 1L (n=57) and 76 were R/R with 1–7 previous LoT. Treatments received included: chemo/CIT (n=98), autologous SCT (n=7), and chemo-free regimens (n=28).2 MRD was assessed in the bone marrow within 6 months of  treatment completion. Patients had to have achieved at least a partial response to therapy to be included in the analysis.

      uMRD = <1  tumour cell per 104 white cells.

      CIT  = chemoimmunotherapy; LoT = line  of  therapy; MRD = minimal  residual disease; OS =  overall survival; R/R = relapsing/remitting; PFS  = progression-free survival; partial response; SCT = stem cell transplant; uMRD = undetectable minimal  residual disease.

      Early deep responses have been associated with improvements in PFS and OS2,3

      In a prospective analysis of the CLL-11 trial, patients who achieved uMRD after frontline Clb+O showed improved long-term survival up to 7 years later, regardless of subsequent therapies taken during that time.3

      7-year OS results according to level of MRD achieved in the peripheral blood with 1L therapy3

      Adapted from Langerak AW et al. 2019.
      uMRD = <1 tumour cell per 104 white cells.

      CLL-11 was an open-label, randomised, 3-arm, Phase 3 study evaluating the efficacy and safety of Clb+O and Clb+R vs Clb alone (stage 1) and Clb+O vs Clb+R (stage 2), in patients with previously untreated CLL and co-morbidites. Only patients included in stage 2 (Clb+O vs Clb+R) were included in this prospective analysis.

      Clb+O = chlorambucil + obinutuzumab; Clb+R = chlorambucil + rituximab; MRD = minimal residual disease; OS = overall survival.

      Explore deep response with VENCLYXTO

      References

      1. Böttcher S, et al. Hematol Oncol Clin North Am. 2013;27(2):267-288.
      2. Kwok M, et al. Blood 2016;128: 2770–2773.
      3. Langerak AW, et al. Blood 2019;133(Suppl.): 494–497.

       

      VENCLYXTO PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCCLL-200348. Date of preparation: October 2020.